Immune map of pancreatic cancer evolution
Official title: Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
Run by First Affiliated Hospital of Zhejiang University · NCT07034339 · Data updated 2026-11-12
This project will collect blood, tissue, imaging, and clinical data from people with pancreatic cancer, benign pancreatic lesions, and healthy volunteers to try to build an AI-based immune map that can detect and track pancreatic cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | May 21, 2025 |
| Main results expected | December 1, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | August 6, 2025 |
| Trial ID | NCT07034339 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are adults with primary pancreatic ductal adenocarcinoma (PDAC), patients with benign pancreatic tumors or IPMN confirmed by imaging/pathology, and healthy volunteers without hepatobiliary-pancreatic disease.
✕Probably not a fit
People with autoimmune disease, immunodeficiency, recent cancer therapy, recent blood transfusion, active infection, coagulation disorders, or those on immunosuppressive drugs are excluded and therefore unlikely to be enrolled or to benefit directly from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The project aims to establish a large, multicenter pancreatic cancer cohort and a standardized clinical biorepository that captures blood, tissue, imaging, and clinical data across disease stages. It will collect paired peripheral (blood) and local (tumor and adjacent tissue) immune samples before and after treatment to characterize temporal and spatial immune changes. Investigators will integrate imaging and clinical information with multimodal immune assays and apply intelligent data-fusion methods to map immune evolution. The effort seeks to identify characteristic immune signatures and to develop an AI model to support earlier and more accurate pancreatic cancer diagnosis and monitoring.
Why it matters
Potential benefit: If successful, this work could enable earlier, more accurate detection of pancreatic cancer and provide immune biomarkers to better track treatment response.
How similar studies have gone: Previous studies combining tumor immune profiling and AI have shown promising results in other cancers, but comprehensive peripheral-to-local immune mapping specifically for pancreatic cancer remains relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy individuals without benign or malignant liver, gallbladder, and pancreas diseases * Primary PDAC * Patients with benign pancreatic tumors * IPMN patients diagnosed by pathology/imaging Exclusion Criteria: * Having autoimmune diseases * Accompanied by other malignant tumors * History of tumor treatment (except thyroid cancer and breast cancer, cured for more than 5 years) * Acute infection * History of blood transfusion within the past 6 months, or use of drugs that affect peripheral blood components such as recombinant human erythropoietin and interleukin within 2 weeks * Organ decompensation dysfunction * Immunodeficiency syndrome * Hematological precancerous lesions * Accept immunosuppressive therapy * Diagnosed coagulation disease
Where it's running
-
the First Affliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Yangyang Wang
- Email: 12418635@zju.edu.cn
- Phone: 13957830918
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liquid biopsy biomarkers to detect and monitor pancreatic cancer
Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.
-
INSPIRE: Putting patient-reported info into multidisciplinary tumor boards
This study tests whether adding electronic patient-reported outcomes to tumor board discussions can help guide treatment decisions for women with breast, gynecologic, pancreatic cancers and related cancers.
-
MRI scan for detecting pancreatic cancer in people at high risk
This study tests a dedicated pancreas MRI (MRP) tool to see if it helps find pancreatic cancer earlier in people with a strong family or genetic risk.
-
Cutting down ultra-processed foods for people at high cancer risk
This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.
-
Carbon nanoparticle‑loaded iron for advanced solid tumors
This test uses direct injections of a carbon nanoparticle‑loaded iron medicine (CNSI‑Fe) to see if it can shrink tumors in adults with advanced solid cancers who have no effective standard treatment options.
-
Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids
This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.